American Century Companies Inc. Raises Stock Holdings in Insmed, Inc. $INSM

Key Points

• American Century Companies Inc. increased its stake in Insmed, Inc. by 7.3%, owning 872,123 shares after purchasing an additional 59,343 shares worth approximately $66.5 million.
• Insider trading activity included director David W. J. Mcgirr selling 3,250 shares and Orlov S. Nicole Schaeffer selling 99,172 shares, contributing to a total of 497,829 shares sold by insiders in the last three months.
• Insmed's quarterly earnings missed expectations with a reported loss per share of ($1.70), compared to the consensus estimate of ($1.30), though revenue grew 18.9% year-over-year.

American Century Companies Inc. grew its stake in shares of Insmed, Inc. (NASDAQ:INSM - Free Report) by 7.3% in the first quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 872,123 shares of the biopharmaceutical company's stock after purchasing an additional 59,343 shares during the quarter. American Century Companies Inc. owned approximately 0.48% of Insmed worth $66,534,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently made changes to their positions in the company. Cullen Frost Bankers Inc. boosted its position in Insmed by 164.9% during the 1st quarter. Cullen Frost Bankers Inc. now owns 355 shares of the biopharmaceutical company's stock valued at $27,000 after buying an additional 221 shares during the period. Elequin Capital LP bought a new position in shares of Insmed during the fourth quarter valued at about $28,000. NBC Securities Inc. purchased a new stake in shares of Insmed during the first quarter worth about $49,000. Versant Capital Management Inc grew its stake in shares of Insmed by 546.3% in the first quarter. Versant Capital Management Inc now owns 698 shares of the biopharmaceutical company's stock worth $53,000 after purchasing an additional 590 shares during the last quarter. Finally, Signaturefd LLC grew its stake in shares of Insmed by 60.0% in the first quarter. Signaturefd LLC now owns 867 shares of the biopharmaceutical company's stock worth $66,000 after purchasing an additional 325 shares during the last quarter.

Analyst Ratings Changes

Several research firms have weighed in on INSM. Stifel Nicolaus increased their price objective on Insmed from $121.00 to $145.00 and gave the stock a "buy" rating in a report on Thursday, August 14th. Jefferies Financial Group raised their price target on Insmed from $129.00 to $148.00 and gave the stock a "buy" rating in a research note on Wednesday, August 13th. Wells Fargo & Company lifted their price target on shares of Insmed from $130.00 to $140.00 and gave the company an "overweight" rating in a report on Tuesday, August 12th. Truist Financial upped their price objective on shares of Insmed from $126.00 to $139.00 and gave the stock a "buy" rating in a report on Thursday, August 14th. Finally, UBS Group raised their target price on shares of Insmed from $124.00 to $133.00 and gave the stock a "buy" rating in a research report on Friday, August 8th. Sixteen investment analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and an average price target of $132.57.

Insider Buying and Selling at Insmed

In other Insmed news, COO Roger Adsett sold 25,000 shares of the business's stock in a transaction on Tuesday, August 19th. The stock was sold at an average price of $127.58, for a total value of $3,189,500.00. Following the sale, the chief operating officer directly owned 105,637 shares of the company's stock, valued at approximately $13,477,168.46. The trade was a 19.14% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CFO Sara Bonstein sold 58,400 shares of the stock in a transaction on Monday, July 21st. The stock was sold at an average price of $102.67, for a total value of $5,995,928.00. Following the completion of the sale, the chief financial officer directly owned 73,505 shares in the company, valued at approximately $7,546,758.35. This represents a 44.27% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 539,694 shares of company stock valued at $53,144,604 in the last ninety days. Corporate insiders own 3.00% of the company's stock.

Insmed Stock Down 0.5%

NASDAQ:INSM traded down $0.72 during mid-day trading on Friday, hitting $131.88. 2,098,255 shares of the company's stock were exchanged, compared to its average volume of 2,822,436. The company has a market cap of $27.88 billion, a PE ratio of -23.10 and a beta of 0.95. The company has a debt-to-equity ratio of 0.45, a current ratio of 6.68 and a quick ratio of 6.33. Insmed, Inc. has a one year low of $60.40 and a one year high of $133.56. The business has a fifty day moving average price of $106.82 and a 200 day moving average price of $85.31.

Insmed (NASDAQ:INSM - Get Free Report) last announced its earnings results on Thursday, August 7th. The biopharmaceutical company reported ($1.70) earnings per share for the quarter, missing analysts' consensus estimates of ($1.30) by ($0.40). Insmed had a negative net margin of 259.82% and a negative return on equity of 195.37%. The business had revenue of $107.42 million for the quarter, compared to the consensus estimate of $104.06 million. During the same period in the prior year, the business posted ($1.94) EPS. Insmed's revenue for the quarter was up 18.9% on a year-over-year basis. Insmed has set its FY 2025 guidance at EPS. Equities analysts predict that Insmed, Inc. will post -4.56 EPS for the current year.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.